This handout explains what is involved in having a lung transplant with the UW Medicine Lung Transplant Program.

Getting Started

We will give you a lot of information about having a lung transplant and the entire transplant process. Please read this information very carefully. Share it with your family and caregivers.

Having a lung transplant changes a person’s life in many ways. Patients must think about everything involved before going forward with the transplant process.

It is normal to feel overwhelmed with all you are learning. Write down any questions you have and bring them to your clinic visit.

What is a lung transplant?

A lung transplant is a treatment option for some people with end-stage lung disease. During the transplant surgery, the surgeon removes one or both diseased lungs. They are replaced with lungs from an organ donor.

A successful outcome after a transplant requires a full commitment from the patient, their family and caregivers, and the entire UW Medicine Lung Transplant Team.

What are the goals of transplant?

The main goals of a lung transplant are to improve quality of life and prolong life. After a lung transplant, most recipients:

- Can breathe better and do not need oxygen support
- Can be more active than they were before the transplant
- Enjoy a better quality of life
Who can have a lung transplant?
To be a candidate for a lung transplant, a patient must have:
• End-stage lung disease that affects their activities of daily living
• A lower life expectancy because of their lung disease
• Tried all other treatments for their lung disease, without success

All transplant programs have criteria for choosing transplant candidates. These criteria help us know if a patient will most likely benefit from a lung transplant. The criteria used by UW Medicine's Lung Transplant Program are included with this handout.

What is involved in having a lung transplant?

Screening
Patients must first have a full health screening before they are placed on the waiting list for a lung transplant. The purpose of the screening is to find any problems that could affect the success of the transplant surgery and the patient’s recovery afterward.

Teamwork
Everyone involved in the transplant process works together as a team. This team includes the patient, their family and caregivers, and the entire UW Medicine Lung Transplant Team.

Commitment
Success depends on the patient’s commitment to the process before, during, and after the lung transplant surgery. This commitment begins with the first clinic visit and continues for the rest of their life. Patients must commit to:
• Taking their medicines as prescribed
• Monitoring their health and new lung(s)
• Practicing healthy living
• Being faithful about visits and follow-up with the Lung Transplant Team

Family and Caregivers
Success also requires the ongoing dedication of the patient’s family and caregivers. Their commitment must last for the rest of the patient’s life.

Ongoing Monitoring
The recipient must be closely monitored after the transplant surgery and for the rest of their life. This lifelong follow-up is vital. It allows us to find any problems early so that tests and treatments can be started right away. All members of the Lung Transplant Team work together to provide the best possible care before, during, and after the transplant surgery.
Being Referred

For a patient to be considered for a lung transplant at UW Medicine, their local healthcare provider must refer them. The referring doctor is usually the lung doctor (pulmonologist) who has been treating the patient’s lung disease. The Lung Transplant Team values input from the patient’s other providers. We will involve them in both the screening process and long-term care.

Screening Process

The screening process begins over the phone. We review the patient’s medical records and ask about their health history. If we do not find any issues that may affect their ability to have a good outcome after a lung transplant, we will set up a first clinic visit.

First Clinic Visit

A doctor who is an expert in lung transplant will review all the patient’s health information. This doctor then meets with the patient to find out if a lung transplant is their best option. The doctor will explain the transplant process and talk about the risks and benefits of having a lung transplant.

A lung transplant is not the right option for every patient. If a lung transplant is not a good option for a patient, the doctor will explain why. We will also talk with the patient’s referring provider about the decision and suggest other treatment options, if possible.

Evaluation

If the patient and the lung transplant doctor decide that a lung transplant may be a good option, the next step is the evaluation. During this process, we set up tests to assess the patient’s lung disease. We also do other studies to make sure the patient does not have any problems with their heart, bones, kidneys, liver, or other organs.

Some of these studies and lab tests can be done by the patient’s local providers. Others must be done at University of Washington Medical Center (UWMC). As each study is done, we review the results to be sure that the patient is still a possible candidate for a transplant.

The evaluation includes visits with everyone on the Lung Transplant Team. Team members include the transplant pulmonologist, the lung transplant surgeon, social worker, financial counselor, and nutritionist. There may be visits with other providers as well.

Evaluation appointments and tests are usually done as outpatient visits. They do not require an overnight stay in the hospital. We do our best to group as many tests or visits as possible into one day to reduce travel time. If the patient cannot do many tests or visits in one day, we can spread them out over more days.
Most evaluations take a few weeks. The process may take longer for some people. The findings from the studies and visits will help us decide if the patient is likely to benefit from a lung transplant.

**Caregivers**

The potential recipient must name at least 2 people who will be their caregivers before the transplant, while they are on the waiting list, and for the rest of their life after transplant. These caregivers must be adults, be able to drive, be nonsmokers, and be able to stay all day at the hospital while the patient is recovering from the transplant surgery.

We do **not** advise depending on paid caregivers. Paid caregivers are:

- Not covered by most insurance after transplant
- Not available for care 24 hours a day, 7 days a week
- Not committed to the lifelong follow-up needed

As part of preparing for a transplant, the patient and their family or caregivers must attend our lung transplant education class. The class explains more about the transplant process, being on the waiting list, the transplant surgery, and what to expect after a lung transplant.

**Decision by the Lung Transplant Recipient Selection Committee**

After the evaluation is done, the UW Medicine Lung Transplant Recipient Selection Committee reviews the results from all the tests and clinic visits. This committee includes all members of the Lung Transplant Team, including the Program Director, Surgical Director, Medical Director, transplant pulmonologists, lung transplant surgeons, lung transplant nurse coordinators, social worker, nutritionist, financial counselor, pharmacist, and other providers as needed. The committee may also review input from the patient’s primary providers and other consultants.

After their review, the committee may decide to:

- Accept the patient as a lung transplant candidate and put their name on the lung transplant waiting list
- Not accept the patient as a lung transplant candidate, and suggest other treatment options, if available
- Ask for more visits and tests before they make their decision

If the committee decides that the patient is not a candidate for a lung transplant at UW Medicine, the lung transplant doctor or lung transplant coordinator will talk with the patient and explain the reasons for their decision. The patient may wish to contact other transplant centers and ask to be evaluated. They can also request that we send their medical records to other centers.
If the committee needs more visits or tests to make their decision, they will meet again to talk about the results after those visits and tests are done. They will then make their final decision about the patient’s candidacy for a lung transplant at UW Medicine.

**Double-Lung or Single-Lung Transplant**

The Lung Transplant Recipient Selection Committee decides if the patient is best suited to receive a double-lung (*bilateral*) transplant or a single-lung transplant. This decision is based on many factors, including the organs that are available. A double-lung transplant may be the only option if the patient has certain types of lung diseases.

**Confirming Insurance Benefits**

After the patient is approved for the waiting list, we must confirm their insurance benefits with their insurance company or designated payer. If needed, the Lung Transplant Program will submit all required information to the payer. We will ask for final approval of benefits for the lung transplant surgery, all follow-up care, and medicines needed after transplant.

**Financing a Lung Transplant**

The UW Medicine Lung Transplant financial counselor will contact the patient and their family or caregivers during the evaluation to go over insurance information. Before moving forward with a lung transplant, the patient should ask their insurance provider if these costs are covered:

- Organ acquisition fee
- The transplant surgery and hospital stay
- Lifetime medicines (including immune-suppressing medicines)
- Home *intravenous* (IV) therapy
- Rehabilitation (inpatient and outpatient physical, occupational, and speech therapy)
- Travel or relocation and housing

The patient should also ask about “lifetime maximums” for any benefits that are paid.

Sometimes, a patient finds out that their insurance will not cover all the costs of a lung transplant. If this happens and the patient cannot afford to cover the costs, the patient and their family may need to do fundraising before being placed on the waiting list.
Traveling to and Staying in the Seattle Area

Since a transplant surgery cannot be “scheduled,” a patient may be called any day of the week and any time of the day or night. When they are called, they must be able to arrive at UWMC within 3 to 4 hours.

As part of the evaluation, the Lung Transplant Recipient Selection Committee will review the patient’s plans for:

- Getting to UWMC within 3 to 4 hours of being called for a lung transplant
- Housing in the Seattle area after the transplant

We want to make sure that there are no issues that might keep the patient from arriving at UWMC in time. We also want to be sure they have a place to live after the transplant surgery.

If the patient:

- **Does not live within driving distance of Seattle:** They may need to plan for air travel. This will allow them to keep living at home and still arrive at UWMC within 3 to 4 hours of “the call.”

- **Cannot travel to UWMC within 3 to 4 hours, either by ground or air:** They must move to Seattle or to a place within 3 to 4 hours’ travel time while they wait for a lung transplant.

For **at least 3 months** after the transplant, the patient and their family or caregivers must live within 1 hour of UWMC. Some patients must stay in the Seattle area for 6 months or longer.

Most insurance providers do not pay for non-emergency travel, caregiver costs, or local housing. Housing is not directly provided by the UW Medicine Lung Transplant Program, so the patient and their family must make these plans if they need to relocate. The Lung Transplant social worker will provide information and resources about travel and housing options.

Waiting List

After the Lung Transplant Recipient Selection Committee accepts the patient as a lung transplant candidate and we receive final approval from their insurance provider, we contact the patient and place them on the waiting list for a lung transplant. If the patient needs to relocate to be closer to Seattle, we will place them on the waiting list after they have relocated.

The United Network for Organ Sharing (UNOS) maintains the waiting list for patients in the United States. The list matches patients waiting for a transplant with a compatible organ donor. Most times, organs are allocated based on how sick a patient is and how long they can expect to live after a
transplant. UNOS uses the Lung Allocation Score (LAS) for this process. To learn more about UNOS and the Lung Allocation Score, visit www.unos.org.

Waiting for a Transplant

A patient may wait a few days or a few years before the right donor organ is found. The most recent Scientific Registry of Transplant Recipients (SRTR) report is included in this packet. This report includes the UW Medicine Lung Transplant Program’s median waiting time for a lung transplant. The median is the middle number in a range of numbers. A median waiting time of 6 months means that half of the patients wait less than 6 months and half wait more than 6 months.

While the patient waits for a lung transplant:

- Their primary care provider and a pulmonologist must continue to manage their medical issues and lung disease.
- They must see a UW Medicine Lung Transplant Program pulmonologist at least every 2 to 3 months. At these visits, we review any changes in their health and update studies or tests as needed. We may also set up other visits with the social worker, dietician, and other providers as needed.

Being Removed from the Waiting List

While waiting for a transplant, a patient may become more ill, develop new health problems, or have other issues. These changes may affect whether a lung transplant is still the best treatment option. If it is not, the patient may be removed from the waiting list.

Patients may also be removed from the waiting list if they lose their insurance, lose their caregivers, or no longer meet our criteria for a lung transplant in some other way. We will talk with the patient and their family or caregivers about any problems that arise. We will do our best to help resolve these problems, if possible.

If a patient is removed from the waiting list and is no longer a candidate for a lung transplant, the Lung Transplant Team and the patient’s other providers will help them explore other treatment options, or end-of-life care and comfort measures as needed.

Donor Lung(s)

The donor lung(s) may come from the Seattle area or a surgical team may drive or fly to another city or state to get the lung(s). When a potential donor is found, the Lung Transplant Team does a full assessment of the donor lung(s) to see if they are suitable for transplant. This process can involve hours or days of tests and review.
Getting “the Call”

If the donor lung(s) seem to be suitable, we call one or more potential recipients to come to UWMC. If we call more than one potential recipient, usually one is a “back-up” recipient. A back-up is needed in case there are any reasons the lung(s) are not a good fit for the first recipient.

To alert the patient about the potential transplant, we call them by phone at the numbers they provided when they were placed on the waiting list. This means that the patient must:

- Tell us right away if their phone numbers change
- Answer all incoming calls or voice messages right away

If the patient does not answer the phone or reply to a voice mail within a short time, we may call another patient to come to UWMC for the transplant.

When the patient arrives at UWMC for the transplant, they are admitted to the hospital. When everything is ready and we confirm that the donor lung(s) are suitable for use, we take the patient to the operating room.

Donor lung(s) that appeared suitable at first may turn out to be not suitable for transplant. Sometimes, the surgical team finds this out when they arrive to get the lung(s). This may happen before or after a potential recipient is called to come to UWMC.

If the donor lung(s) turn out not to be suitable for use, the transplant surgery is canceled. The patient(s) who were called in for transplant are sent home. We call this a “dry run.” Most patients have at least one “dry run” while waiting for a lung transplant.

Hospital Care After Transplant

In the hospital, teams of providers care for lung transplant recipients. These teams follow the recipient during recovery and talk with each other about the recipient’s progress. The names of the providers on the UW Medicine Lung Transplant Team are listed on page 15 of this handout.

- The **Cardiothoracic Intensive Care Unit (CT ICU) Team** provides care while the patient is in the Intensive Care Unit (ICU).

- The **Thoracic Surgery Team** is in charge of the patient’s care in the Thoracic Surgery Unit.

- The **Pulmonary Transplant Team** helps care for the recipient during the entire hospital stay.

- Nurses, nutritionists, physical therapists, occupational therapists, respiratory therapists, and pharmacists also care for the patient.

- Some patients may also need to see other providers. These may be specialists in **endocrinology** (diabetes), **nephrology** (kidney), **gastrointestinal** (stomach and intestines), and **infectious diseases**.
In the CT ICU

A basic single lung transplant surgery takes about 4 to 6 hours. Right after the surgery, the patient goes to the CT ICU. Nurses, doctors, and respiratory therapists assess the patient’s status right away. They begin treatments as needed and get the patient settled into their room. This may take 1 to 2 hours. During this time, we ask family or caregivers to wait in the waiting area just outside the CT ICU.

In the CT ICU, the patient is on a ventilator (breathing machine). This machine provides air through a breathing tube in the mouth. It is used until the patient can breathe on their own.

Sometimes, we can remove the breathing tube a few hours after the surgery, as soon as the patient recovers from the anesthesia (sleeping medicine). Most times, the patient can breathe on their own about 24 to 48 hours after the surgery. If problems arise, they may need to use the ventilator for many days or even weeks.

After a lung transplant, the patient has catheters (tubes) in their arms and neck, a catheter to drain their bladder, and drains in their chest to remove any fluid from around the new lungs. They may also have an epidural catheter for pain medicine. As their condition improves, we remove the catheters and drains.

Most patients stay in the CT ICU for about 3 to 5 days. If there are any problems, they may stay there longer.

In the Thoracic Surgery Unit

Once the patient can breathe on their own and their condition is stable, they move to the Thoracic Surgery Unit. One of our goals on this unit is to prepare the recipient and their family or caregivers for going home. A recipient may stay in this unit a few days to a few weeks, depending on their recovery. The average stay in the hospital is 14 to 20 days.

Some recipients have issues that arise during their recovery. These recipients may need to be in the hospital for several months.

Safety

After the transplant surgery, the recipient has a higher risk of getting infections. To keep the recipient safe, we:

- Ask visitors to wear gloves, a mask, and perhaps a gown
- Ask all adults and children with symptoms of a cold or an infection to wait until they are well to visit the patient.
Getting Ready to Go Home

All members of the Lung Transplant Team help the patient get ready to leave the hospital. We give many teaching sessions about care at home. The recipient and their family or caregivers must attend all of these teaching sessions. This means that the family or caregivers must be with the recipient on the Thoracic Surgery Unit all day, every day, until the recipient leaves the hospital.

In the teaching sessions, the recipient and their family or caregivers learn how to:

- Take all medicines correctly
- Check vital signs (weight, blood pressure, pulse rate, and temperature) and lung function (spirometry)
- Know the signs and symptoms of possible rejection or infection

The recipient is ready to leave the hospital when their condition is stable, they can walk, and they have completed all the teaching sessions.

After Transplant

Transplant Medicines

Every day for the rest of their life, the transplant recipient must take many medicines. Some of these must be taken several times a day. Medicines that help prevent rejection of the transplanted lung(s) are called *immunosuppression* or *immunosuppressive* medicines. The recipient also takes medicines to prevent infection and other problems that may occur after the transplant.

The transplant recipient must take all their medicines as prescribed. If they do not, it may cause severe damage to their lungs, damage to their other organs, or even death.

Transplant medicines can be very costly. UW Medicine’s financial counselors work closely with the patient to make sure they have enough insurance coverage or other resources to cover these costs.

Blood Tests

The transplant recipient must also have blood tests often. These tests check the levels of the medicines in their body. The tests can also show if there are other problems. The doctor may adjust the medicine doses based on these test results.

Recovery

Two caregivers must be able to help during the first stages of recovery. This is needed because a family member or caregiver must stay with the
patient **at all times** for at least the first 3 months after the transplant. Most recipients need help with taking their medicines, cooking meals, paying bills, and doing chores like cleaning and laundry. Some patients may also need help with taking care of the surgery wounds and with personal care like bathing, dressing, and using the toilet.

How soon a lung transplant recipient returns to their usual activities depends on how their recovery goes. Most recipients can resume a good level of activity 4 to 6 weeks after their transplant surgery. By then, they should be able to walk, bathe, and dress themselves.

Recipients must limit use of their arms for at least 8 to 12 weeks after surgery so that their chest can heal. They may also need ongoing physical therapy to help them regain their strength.

### Follow-up Visits

The recipient has many follow-up clinic visits with the UW Medicine Lung Transplant Team. The team will watch them closely for any signs of problems. The recipient’s family or caregivers must:

- **Provide transportation** to all follow-up visits. It is not safe for the recipient to drive for several weeks after the transplant surgery.

- **Come to all follow-up visits** with the recipient so they can learn about changes in the medicines and other treatments.

### Rejection and Infection After Transplant

After a lung transplant, recipients face these ongoing risks:

- Rejection of the new lung(s)
- Infection due to the immune system being suppressed

The immune system’s job is to protect the body against infection and illness. It does this by destroying germs and other substances that may be a threat. To a healthy immune system, a transplanted organ is an “invader” that must be rejected.

To keep their body from rejecting the new lung(s), the recipient must take medicines that suppress their immune system. They must take these medicines for the rest of their life. But, when their immune system is suppressed, the recipient can get infections more easily.

We teach recipients and their family or caregivers about the common signs of infection and rejection. It is vital to notice these signs early and tell the Lung Transplant Team right away. Most times, the recipient has better results if they get checked and begin treatment quickly.
**Rejection**

Different types of rejection can happen after a lung transplant. They include *acute rejection*, *antibody-mediated rejection*, and *chronic rejection*, also known as *chronic lung allograft dysfunction* (CLAD) or *bronchiolitis obliterans syndrome* (BOS).

If we are concerned that the recipient may be rejecting their new lung(s), we may schedule a *bronchoscopy* with lung biopsies, blood tests, and other testing. If the recipient has rejection, they receive treatments based on the type of rejection and how severe it is.

Sometimes rejection can get worse, even with treatment. Rejection may result in lung failure and death.

**Infections**

Many types of infections can occur after a lung transplant. These can include:

- *Bacterial* infections such as pneumonia, skin infections, or infection of other parts of the body
- *Viral* infections such as respiratory viruses (like colds) that can cause damage to the transplanted lung(s)
- *Fungal* or mold infections

We will do our best to treat any infections that occur. Some infections cannot be treated or do not respond to treatment. This can result in lung failure and death.

**Other Problems After Transplant**

There are many other problems that can occur after a lung transplant. Some of these are:

- *Primary graft dysfunction* can occur. This is when the lung(s) do not work as they should right after the transplant surgery. If this happens, recovery may be slower. The recipient may also need to stay in the hospital longer. The recipient may die if the lung(s) do not begin to work.

- Surgical incisions may not heal fully. They also may come apart (*dehiscence*), or become infected. Treatments for incision problems include medicines to fight infection, more dressing changes to the wound, or surgery.

- *Airway* (*bronchial tube*) problems may occur. These problems include airway *stenosis* (narrowing) or airway *dehiscence* (airway falling apart). If these problems occur, the recipient may need a *bronchoscopy* (an exam where a tube with a camera is inserted into the lungs) or surgery to repair the airways, to *dilate* (widen) the airways, or to place a *stent*.
Over time, other problems may also occur. Many of these may be related to the immune-suppressing drugs. Side effects from these drugs include:

- Kidney problems that may require dialysis or a kidney transplant
- Digestive problems
- Blood count problems
- Nerve damage
- High blood pressure
- Weight gain
- Diabetes

Immunosuppressive medicines also increase the risk of getting cancer. Transplant recipients can develop cancers such as skin cancers and a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD). Cancer after a lung transplant can be minor, but it can also be very serious or life-threatening. Patients may need surgeries or chemotherapy to treat these cancers.

**Long-term Follow-up**

After a lung transplant, the recipient must have regular clinic visits with the UW Medicine Lung Transplant Team. These follow-up visits will be needed for the rest of the recipient’s life.

If the recipient lives far away from Seattle, we work closely with their local doctors. But they still must come to UWMC for their regular clinic visits with the UW Medicine Lung Transplant Team.

After the first recovery phase:

- If the recipient is doing well, we do blood tests at least every 4 to 6 weeks. We will then see them for clinic visits several times a year.
- If there are problems, the recipient may need to have testing or clinic visits much more often.

**Long-term Outcomes**

After a lung transplant, most recipients report that they are doing well. Most feel that their quality of life has improved. Some are able to return to work. Others are able to enjoy their retirement, travel, and spend time with their loved ones and friends.

Our goal is for every transplant recipient to improve their quality of life. This does not always occur. Patients who have problems after a lung transplant may need to be hospitalized many times. They may not be able to do normal activities, they may feel short of breath, and they may need extra oxygen. Very rarely, a patient may even feel worse than they did before the lung transplant.
Survival Rates

About 85% to 95% of patients (about 85 to 95 out of 100 patients) who receive a lung transplant are living 1 year after the transplant surgery. The median survival of all lung transplant recipients is about 5½ years. This means that half of lung transplant recipients live less than 5½ years and half live longer.

Recipients in the UW Medicine Lung Transplant Program meet or exceed these expected survival rates.

Survival rates for all transplant programs are on the Scientific Registry of Transplant Recipients (SRTR) website at www.srtr.org. This data is updated every 6 months. The most recent SRTR report is attached.

Commitment and Dedication

A lung transplant is a major event for everyone involved. The patient’s life is changed in many ways. A successful outcome after a lung transplant demands great dedication from the patient, their family and caregivers, and the entire UW Medicine Lung Transplant Team.

The UW Medicine Lung Transplant Team stands with our transplant patients. We are dedicated to providing life-long support, medical care, and teaching for the patient and their family and caregivers.

Please see the handout “UW Medicine Lung Transplant Team” for a full list of providers and staff on our team.
Questions?

Your questions are important. Call the UW Medicine Lung Transplant Team if you have questions or concerns:

Weekdays from 8 am. to 4:30 p.m.: Call 206.598.5668.

After hours and on weekends and holidays: Call 206.598.6190 and ask to page the Pulmonary Transplant fellow on call.

© University of Washington Medical Center
Published PFES: 2017, 2018, 02/2019
Clinician Review: 02/2019
Reprints on Health Online: https://healthonline.washington.edu
Selection Criteria

Lung Transplant Recipient

Patients referred for lung transplantation may undergo a thorough evaluation to determine the cause and stage of lung disease, as well as to see if there are other medical and/or psychosocial conditions that might affect the transplant surgery or the patient’s recovery and long-term outcome after transplant. Each patient may be evaluated by several transplant team members, including a transplant pulmonologist, transplant surgeon, social worker, dietitian, and financial counselor. The patient selection criteria below are designed to ensure fair and non-discriminatory distribution of organs, as well as optimal outcomes after transplant. We do not exclude individuals based on factors such as race, ethnicity, religion, national origin, gender, or sexual orientation.

Patients may be considered for lung transplant when the following conditions are present:

- Severe, irreversible lung problems that affect the patient’s ability to perform activities of daily living and that have failed to improve with other treatment options.
- Reduced life expectancy due to lung disease.

Patients must meet the following criteria in order to be accepted as candidates for lung transplant:

- Reasonable general health other than lung disease.
- Adequate nutritional status.
- Appropriate physical conditioning.
- Have reliable, consistent non-smoking caregivers. This means having people available before and after transplant to provide care. Caregivers will need to be available 24 hours a day to help with many tasks, including helping drive to and from appointments, helping with house care needs, assisting with medications and medical care, and being available to assist if the patient becomes ill. Lung transplant candidates will be required to identify several caregivers, including both a primary caregiver as well as one or more secondary caregivers who could assume care of the patient if the primary caregiver is unavailable or unable to provide all support needs.
- Carry adequate insurance coverage and have financial resources for the transplant, medications, medical care, and general living expenses that will be required both before and after transplant.
- Demonstrate the ability to understand and manage, or have someone help manage, the medical treatments needed to have a successful outcome after transplant. Since transplant is a treatment, not a cure, a patient takes medicines, has regular blood and diagnostic tests, and goes to doctor visits for the rest of his or her life.
Patients who have any of the following conditions will not be considered acceptable candidates for lung transplantation. These are also called “absolute contraindications.” If at any stage in the evaluation an absolute contraindication is identified, further evaluation may not occur.

- Body mass index (BMI) greater than 30.
- Severe heart disease or other severe blood vessel disease that cannot be corrected.
- Untreatable significant disease or impairment in other major organs (such as kidneys, heart, or liver) unless a combined organ transplantation can be performed.
- History of cancer within the past 2 to 5 years, based on the type of cancer, and/or a history of cancer that could be reactivated after transplant due to the effects of the medicines needed after transplant.
- Infection with human immunodeficiency virus (HIV).
- Progressive and active neuromuscular or neurologic disease.
- Age greater than 70 years at the time of referral for lung transplantation.
- Active substance abuse (any tobacco, marijuana, or illegal drug use, and any narcotic, alcohol, or other substance abuse). Some patients may be required to complete a substance abuse therapy program and/or to attend recovery support meetings. Blood and urine testing may be used regularly to verify abstinence from substances.
- Lung colonization with Burkholderia cenocepacia (B.cepacia genomovar III) or other highly resistant infections that are untreatable or inadequately controlled prior to lung transplantation.
- Symptomatic or severe esophageal aperistalsis (a condition where the esophagus does not have any normal contractions).
- Advanced liver disease with cirrhosis on biopsy.
- Acute medical instability, including, but not limited to sepsis, heart attack, and liver failure.
- Uncorrectable bleeding disorder or unwillingness to accept blood products.
- Inability or unwillingness to follow directions outlined by health care providers and caregivers. This includes the inability or unwillingness to reliably take medications, attend all follow up visits, and complete treatments or studies as prescribed. This also includes current non-adherence to medical therapy or a history of repeated or prolonged episodes of non-adherence to medical therapy as well as a mental illness that limits the ability to adhere to a prescribed medical regimen.
- Inability or unwillingness to establish care with local providers who can help manage a patient’s care before and after transplant.
- Absence of an adequate or reliable support system.
- Severely limited ability to move and/or walk with poor rehabilitation potential. This includes the inability or unwillingness to participate in pulmonary rehabilitation and/or physical therapy as directed.

Patients with the following conditions may not be acceptable candidates for lung transplantation, depending on the individual situation. These are also called “relative contraindications.” Multiple relative contraindications may preclude proceeding with transplantation.

- Age greater than 65.
- Poor nutritional status including a body mass index (BMI) less than 18.
- Significant disease or impairment in other major organs such as kidneys, heart, esophagus, or liver.
- Severe heart disease or blood vessel disease that requires treatment. If treatment is necessary to be considered for lung transplantation, a follow-up period will be required to be sure that the treatment has been successful before proceeding with lung transplant.
- Poorly controlled diabetes or severe complications of diabetes.
- Osteoporosis (bone loss) that causes fractures, pain, and/or limited ability to move and/or walk.
- High dose steroids (prednisone) for a long period of time. Patients will need to be on a lower dose for 2-4 weeks prior to being placed on the waiting list.
- Hepatitis B or Hepatitis C. Patients with Hepatitis B or Hepatitis C may require a complete evaluation that could include a liver biopsy.
- Multi-drug resistant organisms in the lung.
- Severe deformity (abnormal shape) of the chest or chest wall. This includes a previous history of radiation treatment to the chest that may cause the chest wall to be unable to move normally.
- Extensive prior surgery involving the chest.
- A mental illness that interferes with care. Patients with a mental illness must be well treated and have a care plan that includes routine psychiatric follow up.
- Abnormal movement or paralysis of the diaphragm.
- History of significant adverse reactions to medicines that will be required after transplant.
- History of seizures with evidence of active seizures and/or auras within the past 6 months.
- Critical or unstable condition such as requiring care in the intensive care unit.
By signing this document you are acknowledging receipt of the information, however this does not imply that you will be accepted for transplant.

__________________________  _________________________  Date:________________________
Signature                           Printed Name
Patient or Legal Guardian

__________________________  _________________________  Date:________________________
Signature                           Printed Name
Transplant Nurse Coordinator

__________________________  _________________________  Date:________________________
Signature                           Printed Name
Transplant Physician
January 15, 2019

We want to share with you the most recent survival results for the Lung Transplant Program at University of Washington Medical Center (UWMC). These results were reported by the Scientific Registry of Transplant Recipients (SRTR) in January 2019.

We are attaching the pages of the report that include patient and graft survival data. The report shows:

- **1-year adult patient survival** at UWMC is 90.18%. This is above the expected patient survival of 89.74% and national patient survival of 89.38%.
- **3-year adult lung patient survival** at UWMC is 75.83%. This is above the expected survival of 73.07% and the national patient survival of 72.52%.
- **1-year adult lung graft survival** at UWMC is 90.2%. This is above the expected survival of 89.2% and national graft survival of 88.85%.
- **3-year adult lung graft survival** at UWMC is 76.15%. This is above the expected survival of 71.92% and the national graft survival of 70.47%.

These outcomes comply with Medicare and United Network for Organ Sharing Membership (UNOS) and Professional Standards Committee outcome requirements. To learn more, please visit the website for the UNOS, the national organization that reports transplant results, at [www.unos.org](http://www.unos.org).

If you have any questions or concerns, please call 206.598.5277.

Sincerely,

Michael S. Mulligan, MD
Director, Lung Transplant Program
Primary Surgeon
University of Washington Medical Center

Erika D. Lease, MD
Lung Transplant Program
Primary Physician
University of Washington Medical Center

*Attachments:*
January 2019 SRTR Report
- 1- and 3-year Adult Graft Survival
- 1- and 3-year Adult Patient Survival
- 1- and 3-year Pediatric Graft Survival
- 1- and 3-year Pediatric Patient Survival
### C. Transplant Information

#### Table C6D. Adult (18+) 1-year survival with a functioning deceased donor graft

<table>
<thead>
<tr>
<th></th>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>129</td>
<td>5,700</td>
</tr>
<tr>
<td>Estimated probability of surviving with a functioning graft at 1 year (unadjusted for patient and donor characteristics)</td>
<td>90.20%</td>
<td>88.85%</td>
</tr>
<tr>
<td>Expected probability of surviving with a functioning graft at 1 year (adjusted for patient and donor characteristics)</td>
<td>89.20%</td>
<td>--</td>
</tr>
<tr>
<td>Number of observed graft failures (including deaths) during the first year after transplant</td>
<td>12</td>
<td>577</td>
</tr>
<tr>
<td>Number of expected graft failures (including deaths) during the first year after transplant</td>
<td>12.75</td>
<td>--</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.95</td>
<td>--</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.52, 1.51]</td>
<td>--</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected graft failure rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected graft failure rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's graft failure rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.52, 1.51], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 5% lower risk of graft failure compared to an average program, but WAUW's performance could plausibly range from 48% reduced risk up to 51% increased risk.

---

#### Figure C3D. Adult (18+) 1-year deceased donor graft failure HR estimate

![Figure C3D. Adult (18+) 1-year deceased donor graft failure HR estimate](image1)

#### Figure C4D. Adult (18+) 1-year deceased donor graft failure HR program comparison

![Figure C4D. Adult (18+) 1-year deceased donor graft failure HR program comparison](image2)

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
C. Transplant Information

Table C7D. Adult (18+) 3-year survival with a functioning deceased donor graft

Single organ transplants performed between 01/01/2013 and 06/30/2015
Deaths and retransplants are considered graft failures

<table>
<thead>
<tr>
<th></th>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>122</td>
<td>4,679</td>
</tr>
<tr>
<td>Estimated probability of surviving with a functioning graft at 3 years (unadjusted for patient and donor characteristics)</td>
<td>76.15%</td>
<td>70.47%</td>
</tr>
<tr>
<td>Expected probability of surviving with a functioning graft at 3 years (adjusted for patient and donor characteristics)</td>
<td>71.92%</td>
<td>--</td>
</tr>
<tr>
<td>Number of observed graft failures (including deaths) during the first 3 years after transplant</td>
<td>29</td>
<td>1,367</td>
</tr>
<tr>
<td>Number of expected graft failures (including deaths) during the first 3 years after transplant</td>
<td>33.78</td>
<td>--</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.87</td>
<td>--</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.59, 1.20]</td>
<td>--</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected graft failure rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected graft failure rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's graft failure rate were precisely the expected rate, the estimated hazard ratio would be 1.0.
** The 95% credible interval, [0.59, 1.20], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 13% lower risk of graft failure compared to an average program, but WAUW's performance could plausibly range from 41% reduced risk up to 20% increased risk.

Figure C5D. Adult (18+) 3-year deceased donor graft failure HR estimate

Figure C6D. Adult (18+) 3-year deceased donor graft failure HR program comparison

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
C. Transplant Information

Table C9D. Pediatric (<18) 1-year survival with a functioning deceased donor graft
Single organ transplants performed between 07/01/2015 and 12/31/2017
Deaths and retransplants are considered graft failures

<table>
<thead>
<tr>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>1</td>
</tr>
<tr>
<td>Estimated probability of surviving with a functioning graft at 1 year (unadjusted for patient and donor characteristics)</td>
<td>100.00%</td>
</tr>
<tr>
<td>Expected probability of surviving with a functioning graft at 1 year (adjusted for patient and donor characteristics)</td>
<td>83.45%</td>
</tr>
<tr>
<td>Number of observed graft failures (including deaths) during the first year after transplant</td>
<td>0</td>
</tr>
<tr>
<td>Number of expected graft failures (including deaths) during the first year after transplant</td>
<td>0.18</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.92</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.11, 2.55]</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected graft failure rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected graft failure rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's graft failure rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.11, 2.55], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 8% lower risk of graft failure compared to an average program, but WAUW's performance could plausibly range from 89% reduced risk up to 155% increased risk.

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
### C. Transplant Information

#### Table C10D. Pediatric (<18) 3-year survival with a functioning deceased donor graft

<table>
<thead>
<tr>
<th></th>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>2</td>
<td>129</td>
</tr>
<tr>
<td>Estimated probability of surviving with a functioning graft at 3 years (unadjusted for patient and donor characteristics)</td>
<td>100.00%</td>
<td>60.80%</td>
</tr>
<tr>
<td>Expected probability of surviving with a functioning graft at 3 years (adjusted for patient and donor characteristics)</td>
<td>60.98%</td>
<td>--</td>
</tr>
<tr>
<td>Number of observed graft failures (including deaths) during the first 3 years after transplant</td>
<td>0</td>
<td>50</td>
</tr>
<tr>
<td>Number of expected graft failures (including deaths) during the first 3 years after transplant</td>
<td>0.99</td>
<td>--</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.67</td>
<td>--</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.08, 1.86]</td>
<td>--</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected graft failure rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected graft failure rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's graft failure rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.08, 1.86], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 33% lower risk of graft failure compared to an average program, but WAUW's performance could plausibly range from 92% reduced risk up to 86% increased risk.

#### Figure C11D. Pediatric (<18) 3-year deceased donor graft failure HR estimate

![Bar chart showing estimated hazard ratios](image)

#### Figure C12D. Pediatric (<18) 3-year deceased donor graft failure HR program comparison

![Scatter plot showing program comparison](image)

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
## C. Transplant Information

### Table C12D. Adult (18+) 1-year patient survival (deceased donor graft recipients)

Single organ transplants performed between 07/01/2015 and 12/31/2017
Retransplants excluded

<table>
<thead>
<tr>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>128</td>
</tr>
<tr>
<td>Estimated probability of surviving at 1 year</td>
<td>90.18%</td>
</tr>
<tr>
<td>(unadjusted for patient and donor characteristics)</td>
<td></td>
</tr>
<tr>
<td>Expected probability of surviving at 1 year</td>
<td>89.74%</td>
</tr>
<tr>
<td>(adjusted for patient and donor characteristics)</td>
<td></td>
</tr>
<tr>
<td>Number of observed deaths during the first year after transplant</td>
<td>12</td>
</tr>
<tr>
<td>Number of expected deaths during the first year after transplant</td>
<td>12.12</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.99</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.54, 1.57]</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected patient death rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected patient death rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's patient death rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.54, 1.57], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 1% lower risk of patient death compared to an average program, but WAUW's performance could plausibly range from 46% reduced risk up to 57% increased risk.

### Figure C15D. Adult (18+) 1-year patient death HR estimate (deceased donor grafts)

![Figure C15D](image)

### Figure C16D. Adult (18+) 1-year patient death HR program comparison (deceased donor grafts)

![Figure C16D](image)

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
C. Transplant Information

Table C13D. Adult (18+) 3-year patient survival (deceased donor graft recipients)
Single organ transplants performed between 01/01/2013 and 06/30/2015
Retransplants excluded

<table>
<thead>
<tr>
<th>Wauw</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>120</td>
</tr>
<tr>
<td>Estimated probability of surviving at 3 years (unadjusted for patient and donor characteristics)</td>
<td>75.63%</td>
</tr>
<tr>
<td>Expected probability of surviving at 3 years (adjusted for patient and donor characteristics)</td>
<td>73.07%</td>
</tr>
<tr>
<td>Number of observed deaths during the first 3 years after transplant</td>
<td>29</td>
</tr>
<tr>
<td>Number of expected deaths during the first 3 years after transplant</td>
<td>31.65</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.92</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.63, 1.27]</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (Wauw)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected patient death rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected patient death rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If Wauw's patient death rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.63, 1.27], indicates the location of Wauw's true hazard ratio with 95% probability. The best estimate is 8% lower risk of patient death compared to an average program, but Wauw's performance could plausibly range from 37% reduced risk up to 27% increased risk.

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
C. Transplant Information

Table C15D. Pediatric (<18) 1-year patient survival (deceased donor graft recipients)
Single organ transplants performed between 07/01/2015 and 12/31/2017
Retransplants excluded

<table>
<thead>
<tr>
<th></th>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>1</td>
<td>103</td>
</tr>
<tr>
<td>Estimated probability of surviving at 1 year (unadjusted for patient and donor characteristics)</td>
<td>100.00%</td>
<td>84.65%</td>
</tr>
<tr>
<td>Expected probability of surviving at 1 year (adjusted for patient and donor characteristics)</td>
<td>84.75%</td>
<td>--</td>
</tr>
<tr>
<td>Number of observed deaths during the first year after transplant</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>Number of expected deaths during the first year after transplant</td>
<td>0.17</td>
<td>--</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.92</td>
<td>--</td>
</tr>
<tr>
<td>95% credible interval for the hazard ratio**</td>
<td>[0.11, 2.57]</td>
<td>--</td>
</tr>
</tbody>
</table>

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected patient death rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected patient death rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's patient death rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.11, 2.57], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 8% lower risk of patient death compared to an average program, but WAUW's performance could plausibly range from 89% reduced risk up to 157% increased risk.

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).
C. Transplant Information

Table C16D. Pediatric (<18) 3-year patient survival (deceased donor graft recipients)
Single organ transplants performed between 01/01/2013 and 06/30/2015
Retransplants excluded

<table>
<thead>
<tr>
<th></th>
<th>WAUW</th>
<th>U.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of transplants evaluated</td>
<td>2</td>
<td>123</td>
</tr>
<tr>
<td>Estimated probability of surviving at 3 years (unadjusted for patient and donor characteristics)</td>
<td>100.00%</td>
<td>62.60%</td>
</tr>
<tr>
<td>Expected probability of surviving at 3 years (adjusted for patient and donor characteristics)</td>
<td>62.76%</td>
<td>--</td>
</tr>
<tr>
<td>Number of observed deaths during the first 3 years after transplant</td>
<td>0</td>
<td>46</td>
</tr>
<tr>
<td>Number of expected deaths during the first 3 years after transplant</td>
<td>0.93</td>
<td>--</td>
</tr>
<tr>
<td>Estimated hazard ratio*</td>
<td>0.68</td>
<td>--</td>
</tr>
</tbody>
</table>

95% credible interval for the hazard ratio** | [0.08, 1.90] | -- |

* The hazard ratio provides an estimate of how University of Washington Medical Center (WAUW)'s results compare with what was expected based on modeling the transplant outcomes from all U.S. programs. A ratio above 1 indicates higher than expected patient death rates (e.g., a hazard ratio of 1.5 would indicate 50% higher risk), and a ratio below 1 indicates lower than expected patient death rates (e.g., a hazard ratio of 0.75 would indicate 25% lower risk). If WAUW's patient death rate were precisely the expected rate, the estimated hazard ratio would be 1.0.

** The 95% credible interval, [0.08, 1.90], indicates the location of WAUW's true hazard ratio with 95% probability. The best estimate is 32% lower risk of patient death compared to an average program, but WAUW's performance could plausibly range from 92% reduced risk up to 90% increased risk.

![Figure C23D. Pediatric (<18) 3-year patient death HR estimate (deceased donor grafts)](image1)

![Figure C24D. Pediatric (<18) 3-year patient death HR program comparison (deceased donor grafts)](image2)

The data reported here were prepared by the Scientific Registry of Transplant Recipients (SRTR) under contract with the Health Resources and Services Administration (HRSA).